Hepatocellular carcinoma vs Non-HCC primary liver tumors
How to tell Hepatocellular carcinoma and Non-HCC primary liver tumors apart when a board question makes them look alike.
HCC is hepatocyte cancer in cirrhosis/HBV/HCV with AFP; cholangiocarcinoma is bile duct cancer with obstructive jaundice; adenoma is estrogen-linked benign hepatocyte tumor with bleeding risk.
Side by side
Cirrhosis or chronic hepatitis risk with weight loss, right upper quadrant pain, vascular invasion tendency, and elevated alpha-fetoprotein.
Cholangiocarcinoma causes progressive obstructive jaundice from bile duct malignancy; hepatic adenoma is a benign hepatocyte tumor linked to estrogen exposure or anabolic steroids.
Malignant transformation of hepatocytes often arises in chronically inflamed or cirrhotic liver and may invade portal or hepatic veins.
Cholangiocarcinoma arises from bile duct epithelium; hepatic adenoma is benign hepatocellular proliferation with hemorrhage or rare malignant transformation risk.
Elevated AFP, arterial enhancement with venous washout, cirrhosis, HBV, HCV, or aflatoxin exposure support HCC.
Cholestatic labs, ductal dilation, and CA 19-9 elevation support cholangiocarcinoma; solitary hypervascular lesion in a young estrogen-exposed patient supports hepatic adenoma.
The trap
All can appear as liver masses, so background liver disease, cholestasis, AFP, and estrogen exposure decide the pattern.
The repair move
For liver masses, first ask malignant hepatocyte, malignant bile duct, or benign hormone-linked hepatocyte lesion.
Try a free question
CoreA patient with chronic hepatitis C cirrhosis develops weight loss and a liver mass showing arterial enhancement with venous washout. Alpha-fetoprotein is elevated. Which diagnosis best fits?
Show answer and explanation
Answer: A. Hepatocellular carcinoma. Cirrhosis or chronic viral hepatitis plus elevated AFP and characteristic vascular imaging points to hepatocellular carcinoma.
Why the other choices are tempting
- B. Cholangiocarcinoma is a bile duct malignancy that more strongly presents with obstructive jaundice.
- C. Hepatic adenoma is a benign hepatocyte tumor linked to estrogen or anabolic steroids.
- D. Focal nodular hyperplasia is benign and classically has a central scar.
- E. Liver abscess would add infectious fever, leukocytosis, and abscess imaging features.
Flashcards
Tap a card to flip it.
What risk setting favors hepatocellular carcinoma?
Cirrhosis, chronic hepatitis B or C, aflatoxin exposure, and elevated AFP favor hepatocellular carcinoma.
What presentation favors cholangiocarcinoma?
Progressive obstructive jaundice with cholestatic labs and bile duct involvement favors cholangiocarcinoma.
Quick answers
What is the fastest way to tell Hepatocellular carcinoma from Non-HCC primary liver tumors?
HCC is hepatocyte cancer in cirrhosis/HBV/HCV with AFP; cholangiocarcinoma is bile duct cancer with obstructive jaundice; adenoma is estrogen-linked benign hepatocyte tumor with bleeding risk.
What is the key clue for Hepatocellular carcinoma?
Cirrhosis or chronic hepatitis risk with weight loss, right upper quadrant pain, vascular invasion tendency, and elevated alpha-fetoprotein.
What is the key clue for Non-HCC primary liver tumors?
Cholangiocarcinoma causes progressive obstructive jaundice from bile duct malignancy; hepatic adenoma is a benign hepatocyte tumor linked to estrogen exposure or anabolic steroids.
What is the common trap with Hepatocellular carcinoma vs Non-HCC primary liver tumors?
All can appear as liver masses, so background liver disease, cholestasis, AFP, and estrogen exposure decide the pattern.